Место рокситромицина в лечении инфекций дыхательных путей


Л.П. Жаркова

Рокситромицин является классическим представителем 14-членных макролидов и имеет ряд клинически значимых особенностей. Фармакодинамические и фармакокинетические свойства рокситромицина в сочетании с высокой безопасностью, подтвержденной многочисленными клиническими исследованиями, высокая эффективность антибиотика вне зависимости от кратности его назначения позволяют данному антибиотику занимать достойное место в лечении инфекций дыхательных путей. Однократный прием в сутки препарата рокситромицина Энпарокси в дозе 300 мг обеспечивает высокую комплаентность и представляется наиболее оптимальным режимом дозирования для взрослых и детей старше 12 лет.

Литература


1. Carbon C. Pocket Pharma: Telithromycin and community-acquired respiratory tract infections. London: Current Medical Group Ltd., 2005.


2. КозловР.С., СиваяО.В., КречиковаО.И., ИванчикН.В. // КМАХ 2010. Т. 12. № 4. С. 329–41.


3. Felmigham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(Suppl. S1):25–37.


4. Jenkins SG, Brown SD, Farrell DS. Trends in antimicrobial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1–4. Ann Clin Microbial Antimicrob 2008;11:7–11.


5. Perez-Trallero E, Martin-Yerrero JE, Mazon A, et al. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996–1997 to 2006–2007). AntimicrobAgents Chemother 2008;54:2953–59.


6. Inoure M, Farrell DJ, Kaneko K, et al. Antimicrobial susceptibility of respiratory tract phatogenes in Japan during PROTEKT years 1–5 (1999–2004). Microb Drug Resist 2008;14:109–17.


7. Blasi F. Atypical pathogens and respiratory tract infections. Eur Respir J 2004;24:171–81.


8. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med 2001;135(9):839–40.


9. Principi N, Esposito S, Cavagna R, et al. Recurrent respiratory tract infections in pediatric age: a population– based survey of the therapeutic role of macrolides. J Chemother 2003; 15(1):53–9.


10. Stelmach I, Podsiadlowicz-Borzecka M, Juralowicz D, et al. Analysis of possible causes of recurrent respiratory tract infections in children from Lodz, Poland. Pneumonol Alergol Pol 2003;71(5–6):237–44.


11. Available from: http://www.bioanalytical.com/info/calendar/99/03hoech.htm


12. Веселов А.В. Клинико-фармакологические аспекты практического применения рокситромицина // Фарматека 2006. № 4. С. 28–37.


13. Available from: http://www.rlsnet.ru/tn_index_id_48528.htm 18.12.2012


14. Phillips I, Pechere J-C, Davies A, et al. Roxithromycin:a new macrolides. Symposium. Paris, 29–30 may1987. J Antimicrob Chemopther 1987;20:1–187.


15. Bryskier A, Bergogne-Berezin E. Macrolides. In: Antibacterial and antifungal Agents. Bryskier A, ed.ASM-Press (Washington DC), 2005.


16. Omura S, editor. Macrolide Antibiotics. 2nd edition. Academic Press; 2002.


17. Bryskier A. Roxithromycin: review of its antimicrobial activity. J Antimicrob Chemother 1998;41:1–21.


18. Schmitz FJ, Sadurski R, Kray A, et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000;45:891–94.


19. Blosser-Middleton R, Sahm D, Thornsberry C, et al. Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000–2001. Clin Microbiol Infect 2003;9:431–36.


20. Perez-Trallero E, Alcorta M, Montes M, et al. Comparative activity of macrolides against H. pylori. In: The 36th International Conference on Antimicrobial Agents and Chemotherapy. New Orleans 1996:abstr. E62.


21. Samra Z, Rosenberg S, Kaufman L. Antibiotic susceptibility of Ureaplasma urealyticum. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice1994:abstr. 146.


22. Samra Z, Rosenberg S, Soffer Y, et al. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. DiagnMicrobiol Infect Dis 2001;39:177–79.


23. Ridgway GL. A review of the in vitro activity of roxithromycin against genital pathogens. J Antimicrob Chemother 1987;20(suppl. B):7–11.


24. Goldstein E, Citron D, Vreni Merrinam C, et al. Activities of Telithromycin (HMR 3647, RU 66647) compares to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antibacterial agents against unusual anaerobes. Antimicrob Agents Chemother 1999;43:2801–805.


25. Uip DE, Lima DM, Amato VS, et al. The use of roxithromycin in diarrhoea caused by Cryptosporidium spp. associated with AIDS. In Proceedings of the 3rd Symposium of New Macrolides, Azalides and Streptogramins, Lisbon 1996:abstr. 7.27. Р. 68.


26. Tanyuksel M, Bas A, Araz E, et al. In vitro efficacy of azithromycin and roxithromycin against Toxoplasma gondii. Turk J Vet Anim Sci 2005; 29: 525–29.


27. Nilsen O. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother 1987; 20(suppl. B):81–8.


28. Markham A, Faulds D. Roxithromycin. An update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 48:297–326.


29. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике, 1998. С. 105–120.


30. Begue P, Kafetzis DA, Albin H, et al. Pharmacokinetics of roxithromycin in paediatrics. JAntimicrob Chemother 1987;20(suppl. B):101–6.


31. Masaki M, Inoue Y, Mashimoto H, et al. Laboratory and clinical studies on RU 28965. Chemotherapy 1988;36(suppl. 4):421–37.


32. Babany G, Roulot D, Chretien P, et al. Pharmacokinetics of single and repeated oral doses of roxithromycin in patients with cirrhosis. In:The 16th Congress of Chemotherapy. Jerusalem1989:abstr. 222.


33. Witt A, Sommer EM, Cichna M, et al. Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 2003;188:816–19.


34. Czeizel AE, Rockenbauer M, Olsen J, et al. A casecontrol teratological study of spiramycin, roxithromycin, oleandomycin and josamycin. Acta ObstetGynecol Scand 2000;79:234–37.


35. Pechere J-C. Clinical evaluation of roxithromycin 300 mg once daily as an alternative to 150 mg twice daily. Diagn Microbiol Infect Dis1992;15(suppl. 4):111S–7S.


36. Schonfeld W, Kirst HA, Editors. MacrolideAntibiotics. Birkhauser Verlag 2002.


37. Available from: Available from www.vidal.ru.


38. Carbon C, Hotton JM, Pepin LF, et al. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. J Antimicrob Chemother 1996;37(suppl. C):151–61.


39. Chatzimanolis E, Marsan N, Lefatzis D, et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother 1998;41(suppl. B):81–4.


40. de Campora E, Camaioni A, Leonardi M, et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect Dis 1992;15(suppl. 4):119S–22S.


41. Camaioni A, Leonardi M. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol InfectDis 1992;15(suppl. 4):119S–22S.


42. Karalus NC, Garrett JE, Lang S, et al. Roxithromycin 150 mg b.i.d. versus amoxicillin 500 mg/ clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice. Infection 1995;23:15–20.


43. De Vlieger A, Druart M, Puttemans M. Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. Diagn Microbiol Infect Dis 1992;15(suppl. 4):123S–127S.


44. Mira E, Benazzo M. A multicenter study on the clinical efficacy and safety of roxithromycin in the treatment of ear-nose-throat infections: comparison with amoxycillin/clavulanic acid. J Chemother2001;13:621–27.


45. Marsac JH. An international clinical trial on the efficacy and safety of roxithromycin in 40,000 patients with acute community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 1992;15(suppl. 4):81S–84S.


46. Gialdroni Grassi G, Grassi C. Clinical application of macrolides and azalides in Legionella, Mycoplasma, and Chlamydia respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (Eds.). New York, etc., 1995: 95–119.


47. Stamboulian D, Fernandez-Macloughlin GJ, Lanoel JL, et al. Clinical evaluation of roxithromycin in 101 children. Br J Clin Pract 1988;42(suppl. 55):115–16.


48. Antela A, Guerrero A, Escudero R, et al. Efficacy and safety of roxithromycin as empiric therapy for lower respiratory tract infections. In: The 2nd International Conference on the Macrolides, Azalides and Streptogramins. Venice 1994:abstr. 278.


49. Karalus NC, Garrett JE, Lang S, et al, A clinical and economic comparison of roxithromycin 150 mg twice daily vs. amoxicillin 500 mg/clavulanic acid 125 mg three times daily for the treatment of lower respiratory tract infections in general practice. Drug Invest 1994;8:179–90.


50. Bazet MC, Blanc F, Chumdermpadetsuk S, et al. Roxithromycin in the treatment of pediatric infections. Br J Clin Pract 1988;42(suppl. 55):117–18.


51. Casellas JM, Rodriguez HA, Fernandez-Macloughlin GJ, et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br J Clin Pract 1988;42(suppl. 55):113–14.


52. Stamboulian D, Perianu M. The efficacy of roxithromycin (300 mg once daily or 150 mg BID) in the treatment of “atypical” pneumonia in an international multicentre study. In: The 17th InternationalCongress of Chemotherapy. Berlin, 1991.


53. Salvarezza C, Villar E, Ballario M. Estudio comparative de la eficacia y tolerancia clinica de roxitromicina vs. amoxicillina en neumopatia extrahospitalarias en pediatria. Prensa Med Argent1989;76:127–30.


54. Guggenbichler JP. First results of a new formulation of roxithromycin: a randomized controlled study in lower respiratory tract infections in infants and children. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon1996:abstr. 13.24.


55. Laurencena E, Forti MJ. Roxithromycin in the treatment of acute otitis media in children. Prensa Med Argent 1992;79:577–79.


56. Самсыгина Г.А. Клиническая эффективность некоторых макролидных антибиотиков при острой инфекции нижних отделов дыхательных путей у детей // Инфекции и антимикробная терапия 2000. Т. 2. № 2.


Похожие статьи


Бионика Медиа